Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that a phase III trial evaluating Nexavar (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by an independent Data Monitoring Committee (DMC).
The details can be read here.
No comments:
Post a Comment